These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29610516)

  • 1. Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series.
    Park S; Evans E; Sandborn WJ; Boland B
    Am J Gastroenterol; 2018 Apr; 113(4):627-629. PubMed ID: 29610516
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab for Resistant Pediatric Crohn Disease.
    Rinawi F; Rosenbach Y; Assa A; Shamir R
    J Pediatr Gastroenterol Nutr; 2016 Apr; 62(4):e34-5. PubMed ID: 25023579
    [No Abstract]   [Full Text] [Related]  

  • 5. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data.
    Tang J; Li Q; Huang Z; Shi L; Guo Q; Li M; Gao X; Chao K
    Dig Liver Dis; 2024 May; 56(5):749-755. PubMed ID: 38281871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Kopylov U; Hanzel J; Liefferinckx C; De Marco D; Imperatore N; Plevris N; Baston-Rey I; Harris RJ; Truyens M; Domislovic V; Vavricka S; Biemans V; Myers S; Sebastian S; Ben-Horin S; González Lama Y; Gilletta C; Ariella BS; Zelinkova Z; Weisshof R; Storan D; Zittan E; Farkas K; Molnar T; Franchimont D; Cremer A; Afif W; Castiglione F; Lees C; Barreiro-de Acosta M; Lobaton T; Doherty G; Krznaric Z; Pierik M; Hoentjen F; Drobne D
    Aliment Pharmacol Ther; 2020 Jul; 52(1):135-142. PubMed ID: 32412134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease.
    Al-Raddadi R; Frances C; Moguelet P; Bachmeyer C; Guégan S
    Acta Derm Venereol; 2017 Mar; 97(3):389-390. PubMed ID: 27722763
    [No Abstract]   [Full Text] [Related]  

  • 8. Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.
    Soufflet N; Boschetti G; Roblin X; Cuercq C; Williet N; Charlois AL; Duclaux-Loras R; Danion P; Mialon A; Faure M; Paul S; Flourie B; Nancey S
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2610-2612. PubMed ID: 30851477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.
    Huff-Hardy K; Bedair M; Vazquez R; Burstein E
    Inflamm Bowel Dis; 2017 Oct; 23(10):E49. PubMed ID: 28858074
    [No Abstract]   [Full Text] [Related]  

  • 10. Ustekinumab as an Induction Agent for Crohn's Disease of the Pouch.
    Singh A; Ghouri Y; Shen B
    Inflamm Bowel Dis; 2018 Apr; 24(5):e12-e13. PubMed ID: 29668974
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
    United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab as the First Biological Agent for Crohn's Disease in a 10-Year-Old Girl.
    Fujita Y; Sugaya T; Tanaka T; Tominaga K; Yoshihara S
    Tohoku J Exp Med; 2021 Sep; 255(1):57-60. PubMed ID: 34588346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
    Khorrami S; Ginard D; Marín-Jiménez I; Chaparro M; Sierra M; Aguas M; Sicilia B; García-Sánchez V; Suarez C; Villoria A; Taxonera C; Velasco-Guardado A; Martínez-González J; Gisbert JP
    Inflamm Bowel Dis; 2016 Jul; 22(7):1662-9. PubMed ID: 27306072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review.
    Costa-Moreira P; Lopes S; Santos AL; Pedrosa AF; Andrade P; Portugal R; Macedo G
    J Crohns Colitis; 2020 Feb; 14(2):274-276. PubMed ID: 31267125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn's Disease Patient Successfully Treated with Ustekinumab.
    Bonomo L; de Moll EH; Li L; Geller L; Gordon MI; Dunkin D
    J Drugs Dermatol; 2020 Mar; 19(3):328-331. PubMed ID: 32550694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab.
    Elmoursi A; Barrett TA; Perry C
    Inflamm Bowel Dis; 2020 Jun; 26(7):e62-e63. PubMed ID: 32386054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab for the treatment of Crohn's disease.
    Hansen T; Targownik LE
    Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.
    Klenske E; Osaba L; Nagore D; Rath T; Neurath MF; Atreya R
    J Crohns Colitis; 2019 Feb; 13(2):267-269. PubMed ID: 30388211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation.
    Rowan CR; Cullen G; Mulcahy HE; Keegan D; Byrne K; Murphy DJ; Sheridan J; Doherty GA
    J Crohns Colitis; 2018 Feb; 12(3):376-378. PubMed ID: 29045603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.